Daratumumab as successful initial therapy for AL amyloidosis with nerve involvement

Shweta Deshpande; Morie A. Gertz; Angela Dispenzieri; Shaji S. Kumar; Sameer A. Parikh; Eli Muchtar

doi:10.1080/10428194.2020.1737688

Daratumumab as successful initial therapy for AL amyloidosis with nerve involvement

Shweta Deshpande, Morie A. Gertz, Angela Dispenzieri, Shaji S. Kumar, Sameer A. Parikh, Eli Muchtar

Hematology

Research output: Contribution to journal › Letter › peer-review

4 Scopus citations

Original language	English (US)
Pages (from-to)	1752-1755
Number of pages	4
Journal	Leukemia and Lymphoma
Volume	61
Issue number	7
DOIs	https://doi.org/10.1080/10428194.2020.1737688
State	Published - Jun 6 2020

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1080/10428194.2020.1737688

Cite this

@article{7977d286641040888450eb09987345da,

title = "Daratumumab as successful initial therapy for AL amyloidosis with nerve involvement",

author = "Shweta Deshpande and Gertz, {Morie A.} and Angela Dispenzieri and Kumar, {Shaji S.} and Parikh, {Sameer A.} and Eli Muchtar",

note = "Funding Information: Shweta Deshpande: None; Morie A. Gertz: Consultancy (Millenium) and honoraria (Celgene, Millenium, Onyx, Novartis, Smith Kline, Prothena, Ionis). Angela Dispenzieri: Research funding (Celgene, Millennium, Pfizer, and Janssen), Travel grant (Pfizer). Shaji Kumar: Consultancy (Celgene, Millennium, Onyx, Janssen, and BMS); and research funding (Celgene, Millennium, Novartis, Onyx AbbVie, Janssen, and BMS). Sameer A. Parikh: Research funding has been provided to the institution from Pharmacyclics, MorphoSys, Janssen, AstraZeneca, TG Therapeutics, and Ascentage Pharma for clinical studies in which Sameer A.Parikh is a principal investigator. Sameer A.Parikh has also participated in Advisory Board meetings of Pharmacyclics, AstraZeneca, Genentech, Gilead, and AbbVie (he was not personally compensated for his participation). Eli Muchtar: None.",

year = "2020",

month = jun,

day = "6",

doi = "10.1080/10428194.2020.1737688",

language = "English (US)",

volume = "61",

pages = "1752--1755",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "7",

}

TY - JOUR

T1 - Daratumumab as successful initial therapy for AL amyloidosis with nerve involvement

AU - Deshpande, Shweta

AU - Gertz, Morie A.

AU - Dispenzieri, Angela

AU - Kumar, Shaji S.

AU - Parikh, Sameer A.

AU - Muchtar, Eli

N1 - Funding Information: Shweta Deshpande: None; Morie A. Gertz: Consultancy (Millenium) and honoraria (Celgene, Millenium, Onyx, Novartis, Smith Kline, Prothena, Ionis). Angela Dispenzieri: Research funding (Celgene, Millennium, Pfizer, and Janssen), Travel grant (Pfizer). Shaji Kumar: Consultancy (Celgene, Millennium, Onyx, Janssen, and BMS); and research funding (Celgene, Millennium, Novartis, Onyx AbbVie, Janssen, and BMS). Sameer A. Parikh: Research funding has been provided to the institution from Pharmacyclics, MorphoSys, Janssen, AstraZeneca, TG Therapeutics, and Ascentage Pharma for clinical studies in which Sameer A.Parikh is a principal investigator. Sameer A.Parikh has also participated in Advisory Board meetings of Pharmacyclics, AstraZeneca, Genentech, Gilead, and AbbVie (he was not personally compensated for his participation). Eli Muchtar: None.

PY - 2020/6/6

Y1 - 2020/6/6

UR - http://www.scopus.com/inward/record.url?scp=85081919484&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85081919484&partnerID=8YFLogxK

U2 - 10.1080/10428194.2020.1737688

DO - 10.1080/10428194.2020.1737688

M3 - Letter

C2 - 32159403

AN - SCOPUS:85081919484

VL - 61

SP - 1752

EP - 1755

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 7

ER -

Daratumumab as successful initial therapy for AL amyloidosis with nerve involvement

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this